7 assets in Anal Canal Carcinoma

Therapeutic assets addressing Anal Canal Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fluorouracilum Anal Canal Carcinoma	ECOG-ACRIN Cancer Research Group	P2	B (57)
Toripalimab Anal Canal Carcinoma	Sun Yat-sen University	P2	B (57)
Capecitabine Anal Canal Carcinoma	ECOG-ACRIN Cancer Research Group	P2	CCC (53)
Fludeoxyglucose Anal Canal Carcinoma	ECOG-ACRIN Cancer Research Group	P2	CCC (53)
Ipilimumab Anal Canal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Muamycin Anal Canal Carcinoma	ECOG-ACRIN Cancer Research Group	P2	CCC (53)
Nivolumab Anal Canal Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)